BioSpace News Archive

Program offers more convenience for blood stem cell donors, more reliability for patients and physicians

KBL Merger Corp. IV (NASDAQ: KBLM or the “Company”), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive agreement to acquire 180 Life Sciences Corp. (“180 Life Sciences”), today announced that 180 Sciences Corp. continues to expand their robust IP portfolio.

Endo International plc (NASDAQ: ENDP) today announced the release of its first Environmental, Social and Governance (ESG) report, titled 2019 Corporate Responsibility Report: Helping Everyone We Serve Live Their Best Life.

ZERO TO THREE, the leading nonprofit dedicated to ensuring all babies and toddlers have a strong start in life, announced today the first-ever winners of the Infant and Early Childhood Mental Health (IECMH) Emerging Leadership Award, honoring two emerging leaders in the field of infant and early childhood mental health.

Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, is pleased to announce that the Company has entered into an agreement with a new medical partner located in the USA, to build a customized head mounted display system for assisted medical cancer surgery.

Elorac Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class, proprietary drugs, announced it has amended its current clinical trial evaluating the safety and efficacy of topically applied naloxone hydrochloride lotion, 0.5%, for the treatment of moderate or severe pruritus in patients with the mycosis fungoides or Sézary Syndrome forms of Cutaneous T-cell Lymphoma (CTCL). The original d

Detect Lysosomal Storage Diseases program reduces barriers to genetic diagnosis through sponsored testing for lysosomal storage disorders, including GM2 gangliosidosis

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Friday, November 6, 2020 , at 8:30 a.m. ET . A news release detailing the quarterly results will be made available that day at 6:30 a.m. ET .

Conformis, Inc. (NASDAQ:CFMS) today announced preliminary, unaudited, revenue results for the third quarter ended September 30, 2020. Expected Q 3 Summary: Total revenue of approximately $16.1 million, down 7% year-over-year on a reported and constant currency basis Royalty revenue of $0.1 million Product revenue of approximately $16.0 million, down 7% year-over-year on a reported and constant currency basis - U.S. product revenu

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and related disorders, successfully convened the inaugural meeting of its Scientific Advi